Anti-Lewis Y Recombinant Antibody (BR55-2) (CAT#: TAB-0018CL)

Figure 1 Anti-Lewis Y monoclonal antibody BR55-2 induced caspase-3/7 activation in HCC1954.

HCC1954 (A) or MCF-7 (B) cells were incubated with various concentrations of BR55-2 and, after 24 hours of incubation, caspase-3 activity was measured. Two-way ANOVA with Bonferroni post-test was performed and P values are shown. Bar heights ± error bars denote means ± SDs of three technical replicates.

Hutchins, L. F., Makhoul, I., Emanuel, P. D., Pennisi, A., Siegel, E. R., Jousheghany, F., ... & Kieber-Emmons, T. (2017). Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects. Oncotarget, 8(58), 99161.

Figure 2 Anti-Lewis Y monoclonal antibody BR55-2 induced caspase-3/7 growth inhibition in HCC1954.

The effect of BR55-2 on cell survival was measured after 24 (A) and 48 (B) hours of incubation using CCK-8 kit. Symbols ± error bars at each tested antibody concentration denote means ± SDs of three technical replicates. BR55-2 negatively affected viability of HCC1954 cells at all concentrations after 24 and 48 hours (P < 0.001), while no statistically signicant growth inhibition was observed in MCF-7 cells (P> 0.05).

Hutchins, L. F., Makhoul, I., Emanuel, P. D., Pennisi, A., Siegel, E. R., Jousheghany, F., ... & Kieber-Emmons, T. (2017). Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects. Oncotarget, 8(58), 99161.